Scion

Name

Scion

Legal name

Petrichor Scion Therapeutics Management, LLC

Website

https://scionlifesciences.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Life Sciences Venture Capital

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Life sciences venture capital
• Biotechnology investment
• Therapeutic company building
• Venture fund management
• Biotech incubation services

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Venture Capital Fund Management: Scion generates returns through management fees and carried interest from its $310 million inaugural fund. The firm invests in biotech companies from pre-seed through IPO and beyond, with ability to deploy $60 million or more per portfolio company over the investment lifecycle.
2. Portfolio Company Value Creation: Returns generated through equity appreciation and exits (M&A or IPO) of portfolio companies. The 13 companies the team previously built collectively generated >$34 billion in combined public equity value and announced M&A proceeds.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Scion Life Sciences is a New York City-based life sciences venture capital firm that founds and builds biotechnology companies developing clinically transformational or curative medicines. It deploys long-duration capital from its $310 million inaugural fund, supporting portfolio companies from initial incubation through IPO, and supplements capital with in-house R&D capabilities via Scion Innovations for protein therapeutics and biologics discovery.

Product overview

Scion Life Sciences is a life sciences venture capital firm that operates as an affiliate of Petrichor. Rather than offering a traditional product suite, the firm provides venture capital funding, company-building expertise, and operational resources to found and build exceptional biotechnology companies. The firm has established Scion Innovations as its internal incubation hub providing in-house R&D capabilities focused on protein therapeutics and biologics discovery and development.

Differentiator

Problem solved

Functional benefit

Products and services

• Scion Innovations Scion's internal incubation hub providing in-house R&D capabilities and operational resources to evaluate and create therapeutic molecules, including antibody discovery, protein engineering, multi-specific antibodies, biochemical and functional assay testing, protein expression and purification, and in vitro and in vivo characterization of drug candidates.
• Scion Inaugural Life Sciences Fund Oversubscribed $310 million venture capital fund offered to institutional limited partners, structured to enable investments as small as a few thousand dollars in speculative incubation and to cumulatively deploy $60 million or more per portfolio company from pre-seed through IPO and beyond.
• Scion Fellowship Program Structured fellowship program that recruits exceptional scientists and researchers to work with Scion, with alumni transitioning into full-time roles on the investment team.

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Academic InstitutionscoreStrategic or Co-development PartnerScion sources innovation from academic partners and collaborates with academic founders. The team includes former academic researchers, and the Scion Fellows program recruits from academic backgrounds. Sam Hall was previously an immunologist at University of Cambridge.

Scale indicators7 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Atlas Venture: Boston-based biotech-focused venture capital firm that builds companies from inception with a similar company-creation model. Atlas Venture operates multiple early-stage biotech funds and sources from academic institutions, making it one of the closest direct competitors to Scion's approach.
• Flagship Pioneering: Biotech creation firm that originates companies from internal scientific hypotheses, similar to Scion Innovations. Flagship Pioneers operates dedicated innovation labs and has spawned companies like Moderna, directly paralleling Scion's internal-incubation model.
• ARCH Venture Partners: Large biotech-focused venture capital firm that builds companies around breakthrough science from universities and research institutions. ARCH's model of long-term capital and active company-building mirrors Scion's patient-capital and high-conviction approach.
• Third Rock Ventures: Boston-based biotech creation firm focused on founding and building transformative life sciences companies. The firm specializes in launching newcos around platform technologies and validated biology — nearly identical thesis to Scion's three investment pillars.
• 5AM Ventures: Biotech-focused venture capital firm that creates and invests in early-stage life sciences companies. 5AM has a similar scientific founder-focused model and invests across therapeutics, mirroring Scion's strategy of company formation from compelling science.
• Medicxi: European life sciences venture capital firm focused on founding and investing in single-asset biotech companies. Scion co-founder Aaron Kantoff was previously a Venture Partner at Medicxi, providing direct lineage and a comparable asset-centric investment approach.
• Vida Ventures: Biotech venture capital firm founded by serial entrepreneurs focused on creating and building transformative therapeutics companies. One of Scion's associates previously completed a fellowship at Vida Ventures, indicating overlapping networks and approach.
• Apple Tree Partners (ATP): Healthcare and life sciences venture capital firm where both Scion co-founders (Hall and Kantoff) were previously Partners. ATP is a direct predecessor organization to Scion in terms of investment approach and team lineage, with prior shared deals in Stoke, Chinook, Marengo, and Ascidian.

Broad incumbents

• OrbiMed Advisors: Large healthcare-focused investment firm across venture, growth, and public equities where Scion co-founder Tadd Wessel was previously a Partner. OrbiMed is a much larger incumbent with broader stage and strategy coverage but competes in the same biotech deal sourcing market.

Others

• Petrichor: Healthcare-focused private investment firm and Scion's parent affiliate. Petrichor has deployed $6B+ across 125+ healthcare investments and provides Scion with operational, fundraising, and sourcing infrastructure. Technically related rather than competitive, but operates in adjacent life sciences investing territory.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/scion-life-sciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scion